Enhancing therapeutic vaccination by blocking PD-1–mediated inhibitory signals during chronic infection

Therapeutic vaccination is a potentially promising strategy to enhance T cell immunity and viral control in chronically infected individuals. However, therapeutic vaccination approaches have fallen short of expectations, and effective boosting of antiviral T cell responses has not always been observed. One of the principal reasons for the limited success of therapeutic vaccination is that virus-specific T cells become functionally exhausted during chronic infections. We now provide a novel strategy for enhancing the efficacy of therapeutic vaccines. In this study, we show that blocking programmed death (PD)-1/PD-L1 inhibitory signals on exhausted CD8+ T cells, in combination with therapeutic vaccination, synergistically enhances functional CD8+ T cell responses and improves viral control in mice chronically infected with lymphocytic choriomeningitis virus. This combinatorial therapeutic vaccination was effective even in the absence of CD4+ T cell help. Thus, our study defines a potent new approach to augment the efficacy of therapeutic vaccination by blocking negative signals. Such an approach may have broad applications in developing treatment strategies for chronic infections in general, and perhaps also for tumors.

[1]  D. McGavern,et al.  IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection , 2008, The Journal of experimental medicine.

[2]  J. Church Upregulation of PD-1 Expression on HIV-Specific CD8+ T Cells Leads to Reversible Immune Dysfunction , 2007, Pediatrics.

[3]  Scott N. Mueller,et al.  Regulation of Homeostatic Chemokine Expression and Cell Trafficking During Immune Responses , 2007, Science.

[4]  R. Koup,et al.  SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. , 2007, Blood.

[5]  G. Gao,et al.  PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. , 2007, Blood.

[6]  Lieping Chen,et al.  B7-H1 Up-Regulation on Myeloid Dendritic Cells Significantly Suppresses T Cell Immune Function in Patients with Chronic Hepatitis B1 , 2007, The Journal of Immunology.

[7]  E. Wherry,et al.  Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection , 2007, The Journal of experimental medicine.

[8]  G. Freeman,et al.  Elevated Expression Levels of Inhibitory Receptor Programmed Death 1 on Simian Immunodeficiency Virus-Specific CD8 T Cells during Chronic Infection but Not after Vaccination , 2007, Journal of Virology.

[9]  G. Missale,et al.  Dysfunction and functional restoration of HCV‐specific CD8 responses in chronic hepatitis C virus infection , 2007, Hepatology.

[10]  A. Bertoletti,et al.  Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection , 2007, Journal of Virology.

[11]  R. Koup,et al.  SIV-specific CD 8 T cells express high levels of PD 1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac 251 infection , 2007 .

[12]  G. Freeman,et al.  Liver-Infiltrating Lymphocytes in Chronic Human Hepatitis C Virus Infection Display an Exhausted Phenotype with High Levels of PD-1 and Low Levels of CD127 Expression , 2006, Journal of Virology.

[13]  J. Klarquist,et al.  Loss of IL‐7 receptor alpha‐chain (CD127) expression in acute HCV infection associated with viral persistence , 2006, Hepatology.

[14]  W. Haining,et al.  Resolution of a chronic viral infection after interleukin-10 receptor blockade , 2006, The Journal of experimental medicine.

[15]  L. Teyton,et al.  Interleukin-10 determines viral clearance or persistence in vivo , 2006, Nature Medicine.

[16]  R. Koup,et al.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection , 2006, The Journal of experimental medicine.

[17]  B. Walker,et al.  HIV-specific CD8 T cells express low levels of IL-7Ralpha: implications for HIV-specific T cell memory. , 2006, Virology.

[18]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[19]  M. Massari,et al.  PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion , 2006, Journal of Virology.

[20]  M. Murray,et al.  Recent development of therapeutics for chronic HCV infection. , 2006, Antiviral research.

[21]  R. Balderas,et al.  Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction , 2006, Nature Medicine.

[22]  D. McGavern,et al.  Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. , 2006, The Journal of clinical investigation.

[23]  G. D'offizi,et al.  Accumulation of dysfunctional effector CD8+ T cells in the liver of patients with chronic HCV infection. , 2006, Journal of hepatology.

[24]  P. Romero,et al.  Distinct Mechanisms Control Human Naive and Antigen-Experienced CD8+ T Lymphocyte Proliferation1 , 2006, The Journal of Immunology.

[25]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[26]  B. Verrier Therapeutic vaccination for chronic infectious diseases: lessons from HIV-1. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[27]  M. Mancini-Bourgine,et al.  Therapeutic vaccination against chronic hepatitis B virus infection. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[28]  Denis Puthier,et al.  Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV , 2005, AIDS.

[29]  P. Klenerman,et al.  T cells and viral persistence: lessons from diverse infections , 2005, Nature Immunology.

[30]  E. Wherry,et al.  Low CD8 T-Cell Proliferative Potential and High Viral Load Limit the Effectiveness of Therapeutic Vaccination , 2005, Journal of Virology.

[31]  B. Rehermann,et al.  Immunology of hepatitis B virus and hepatitis C virus infection , 2005, Nature Reviews Immunology.

[32]  E. Wherry,et al.  Antigen-independent memory CD8 T cells do not develop during chronic viral infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[33]  E. Wherry,et al.  Memory CD8 T-Cell Differentiation during Viral Infection , 2004, Journal of Virology.

[34]  K. Mills,et al.  Hepatitis C virus non‐structural protein 4 suppresses Th1 responses by stimulating IL‐10 production from monocytes , 2003, European journal of immunology.

[35]  H. Van Vlierberghe,et al.  A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C , 2003, Hepatology.

[36]  L. Romics,et al.  Hepatitis C Virus Core and Nonstructural Protein 3 Proteins Induce Pro- and Anti-inflammatory Cytokines and Inhibit Dendritic Cell Differentiation1 , 2003, The Journal of Immunology.

[37]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[38]  E. Wherry,et al.  Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment , 2003, Journal of Virology.

[39]  B. Dikici,et al.  Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection , 2003, The Pediatric infectious disease journal.

[40]  D. Montefiori,et al.  Vaccination of Macaques with Long-Standing SIVmac251 Infection Lowers the Viral Set Point After Cessation of Antiretroviral Therapy1 , 2002, The Journal of Immunology.

[41]  E. Wherry,et al.  Differential Sensitivity of Naive and Memory CD8+ T Cells to Apoptosis in Vivo1 , 2002, The Journal of Immunology.

[42]  B. Walker,et al.  Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection. , 2002, Current opinion in immunology.

[43]  I. Williams,et al.  Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. , 2002, Vaccine.

[44]  D. Moskophidis,et al.  Critical Role for Alpha/Beta and Gamma Interferons in Persistence of Lymphocytic Choriomeningitis Virus by Clonal Exhaustion of Cytotoxic T Cells , 2001, Journal of Virology.

[45]  D. Subirá,et al.  Hepatitis B virus–specific T‐cell proliferation and cytokine secretion in chronic hepatitis B e antibody–positive patients treated with ribavirin and interferon alfa , 2001 .

[46]  D. Watkins,et al.  Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques , 2000, Nature Medicine.

[47]  A. Sette,et al.  Vaccination to treat persistent viral infection , 2000, Virology.

[48]  D. Vergani,et al.  Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. , 1999, Gastroenterology.

[49]  M. Moroni,et al.  Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection. , 1996, Blood.

[50]  R. Gish,et al.  Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre‐ and posttreatment with interferon alfa , 1996, Hepatology.